Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report by Takamochi, Kazuya et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Medical Case Reports
Open Access Case report
Readministration of gefitinib in a responder after treatment 
discontinuation due to gefinitib-related interstitial lung disease: a 
case report
Kazuya Takamochi*, Kazuya Suzuki, Abul Hasan Muhammad Bashar, 
Kiyoshige Yajima, Takahiro Mochizuki, Toru Itaya and Kazuhito Funai
Address: First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 435-3192 Japan
Email: Kazuya Takamochi* - ktakamoc@hama-med.ac.jp; Kazuya Suzuki - kazuya36@hama-med.ac.jp; Abul Hasan 
Muhammad Bashar - ahmbashar@yahoo.com; Kiyoshige Yajima - k-yaji@hospital.fujinomiya.shizuoka.jp; 
Takahiro Mochizuki - tmochizu@hama-med.ac.jp; Toru Itaya - t-itaya@hama-med.ac.jp; Kazuhito Funai - kfunai@hmedc.or.jp
* Corresponding author    
Abstract
Introduction: Gefitinib is a new molecular-targeted agent for the treatment of patients with
advanced non-small cell lung cancer that fail to respond to conventional chemotherapy. Gefitinib is
considered to be well tolerated and less toxic compared with conventional cytotoxic drugs.
However, interstitial lung disease (ILD) has been reported as a serious adverse effect. The precise
management of a gefitinib responder having severe adverse events remains unknown.
Case Presentation: We report the case of gefitinib readministration in a patient with lung
adenocarcinoma who had once responded but in whom treatment had to be discontinued owing
to gefinitib-related ILD. A dramatic response was achieved both at the time of initial treatment (250
mg/day) and at readministration of gefitinib (125 mg/day). The effectiveness of gefitinib therapy in
our patient could be explained in part by the presence of an activating mutation of epidermal
growth factor receptor (EGFR) gene, L858R in exon 21, which was identified in the primary tumor.
Conclusion: A reduced dose of gefitinib might be sufficient for patients having tumors with EGFR
gene mutations, and that the currently approved dose may be excessively potent in some of these
patients, thus resulting in the onset of adverse events.
Introduction
Gefitinib is a new molecular-targeted agent for the treat-
ment of patients with advanced non-small cell lung cancer
that fail to respond to conventional chemotherapy. Early
clinical trial data demonstrated that gefitinib was well tol-
erated and was less toxic compared with conventional
cytotoxic drugs[1,2]. The most common adverse events
were skin rash and diarrhea, which are reversible with dis-
continuation of treatment. However, gefitinib-related
interstitial lung disease (ILD) has been reported as a seri-
ous adverse effect of gefitinib therapy [3,4]. The largest ret-
rospective study conducted by the West Japan Thoracic
Oncology Group (WJTOG) showed an overall prevalence
of 3.5% and a mortality of 1.6% [4] Although the precise
mechanism of gefitinib-related ILD remains unknown,
the WJTOG study showed in a multivariate analysis that
male sex, a history of smoking, and the coexistence of
interstitial pneumonia were all significant risk factors.
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We herein report a thought-provoking case of readminis-
tration of gefitinib in a patient with lung adenocarcinoma
who had previously responded and developed gefinitib-
related ILD. Gefitinib readministration with 50% dose
was successful in managing disease progression.
Case presentation
A 56-year-old male was referred to our hospital because of
a lung nodule detected on population-based radiological
screening. He was a current smoker with a smoking index
of 15 pack-years. A chest computed tomography (CT) scan
demonstrated a15 mm solid-density nodule with pleural
indentation in the left lower lobe. Mediastinal lymph
nodes were not swollen in the mediastinal setting images
(clinical T1N0M0, stage IA). He underwent left lower
lobectomy and systematic lymphadenectomy. He was
diagnosed as having lung adenocarcinoma with multiple
mediastinal lymph node metastases and solitary pulmo-
nary metastasis (pathological T4N2M0, stage IIIB). He
received two courses of postoperative adjuvant chemo-
therapy (carboplatin/paclitaxel).
Multiple bone metastases developed 10 months after the
operation. He received two courses of chemotherapy (cis-
platin/docetaxel) and palliative irradiation therapy. Sub-
sequently, at 17 months after the operation, a follow-up
CT scan indicated miliary pulmonary metastases with
lymphangitis carcinomatosa throughout both lungs and
mediastinal lymphadenopathy (Figure 1a). ILD was not
evident on a chest CT scan. No respiratory symptoms were
noted. Multiple brain metastases were simultaneously
detected on brain magnetic resonance imaging. The oral
administration of gefitinib 250 mg/day and whole brain
irradiation therapy (total 30 Gy/12 fr) were initiated. A
rapid improvement in multiple pulmonary metastases
was observed 14 days after the administration of gefitinib
(Figure 1b). Brain metastatic lesions showed a mild
regression.
However, the patient developed progressive general
fatigue and shortness of breath 45 days after the initiation
of gefitinib therapy. A chest CT scan demonstrated new
areas of patchy ground glass opacity (GGO) accompanied
by interstitial markings bilaterally, without evidence of
tumor growth (Figure 2a). The serum LDH level was ele-
vated to 457 IU/L (cut-off: 208 IU/L). To rule out infec-
tious etiologies, we performed sputum cultures and
relevant stainings for bacteria, fungi, and pneumocystis
carinii, and the cytomegalovirous antigen test. None of
these examinations were positive. Because of severe respi-
ratory dysfunction, we could not perform bronchoscopy
with bronchoalveolar lavage. Cardiogenic etiology was
also excluded by electrocardiogram and echo cardiogram.
Based on these findings, he was diagnosed as having gefit-
inib-related ILD, and gefitinib therapy was stopped. He
was treated with high-dose corticosteroid (1 g/day of
intravenous methylpredonisolone for three days) fol-
lowed by a maintainace dose of 50 mg/day of oral pred-
nisolone. The dose of oral prednisolone was decreased by
10 mg per week. After one month of steroid therapy, the
patient reported marked improvement of dyspnoea. A
chest CT scan showed resolution of GGO areas and inter-
stitial markings, however the pulmonary metastatic
lesions had slightly grown (Figure 2b). The serum LDH
level was normalized two months after the initiation of
steroid therapy.
In the five months following the withdrawal of gefitinib,
miliary pulmonary metastases with lymphangitis carcino-
matosa gradually progressed (Figure 3a). The patient was
confined to bed due to severe dyspnoea and rapidly pro-
gressing hypoxia. He was judged to be intolerant to fur-
ther cytotoxic chemotherapy in consideration of his
physical condition. He and his family strongly desired the
readministration with gefitinib rather than palliative care.
Gefitinib therapy with 50% dose (125 mg/day) was there-
fore initiated, after receiving informed consent for the use
of an unproven treatment dose of gefitinib and the high
Radiological evaluation of response to initial treatment with  gefitinib on CT cans Figure 1
Radiological evaluation of response to initial treatment with 
gefitinib on CT cans. (a) before treatment, (b) after treat-
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risk of ILD relapse. Fortunately, the symptoms rapidly
improved one week after therapy was resumed. A chest CT
scan taken one month later showed a significant response
(Figure 3b). Thereafter, disease progression of pulmonary
and bone metastases was documented 6 months after
readministration of gefitinib. His general condition grad-
ually deteriorated with disease progression, and he
expired 16 months after the readministration of gefitinib.
Because he gave his written informed consent to let us use
surgically resected specimens for genetic analyses before
operation, a mutation analysis of the epidermal growth
factor receptor (EGFR) gene was conducted at Mitsubishi
Kagaku Bio-Clinical Laboratories, Inc. Genomic DNA was
prepared from a paraffin-embedded section using macro-
dissection in a surgically resected primary tumor speci-
men. The peptide nucleic acid-locked nucleic acid PCR
clamp protocol [5] was used to perform a mutation anal-
ysis. One of the most common activating mutations,
L858R in exon 21, was identified.
Discussion
The precise management of a gefitinib responder having
severe adverse events remains unknown. There are only
two case reports on readministration of gefitinib in
responders following treatment discontinuation due to
severe gefitinib-related hepatotoxicity [6,7]. Although the
resumption of gefitinib (250 mg/day) and concurrent
steroid therapy [6] failed to control hepatotoxicity, inter-
mittent schedule of gefitinib administration (250 mg/day
once every 5 days) [7] not only successfully reduced hepa-
totoxicity but also induced disease regression.
To the best of our knowledge, this is the second report of
readministration of gefitinib in a patient who had once
developed gefinitib-related ILD. Yano et al [8] previously
reported the readministration of gefitinib in a responder
after discontinuation owing to ILD(alveolar hemorrhage).
Starting with 250 mg/day, gefitinib was given every other
day after blepharitis developed at the time of initial treat-
ment. This intermittent schedule of gefitinib administra-
tion was effective both for the initial treatment and the
resumed treatment.
The currently approved dose of gefitinib was determined
based on the data from two large phase II trials (IDEAL 1
and 2). Similar efficacy but higher toxicity was observed
with the 500 mg dose. Consequently, 250 mg has been
Radiological evaluation of response to re-treatment with  gefitinib on CT scans Figure 3
Radiological evaluation of response to re-treatment with 
gefitinib on CT scans. (a) before re-treatment, (b) after re-
treatment.
Radiological evaluation of gefitinib-related interstitial lung dis- ease on CT scans Figure 2
Radiological evaluation of gefitinib-related interstitial lung dis-
ease on CT scans. (a) before treatment, (b) after treatment.Journal of Medical Case Reports 2007, 1:138 http://www.jmedicalcasereports.com/content/1/1/138
Page 4 of 5
(page number not for citation purposes)
the recommended dose [9,10]. However, anti-tumor
activity was not necessarily dependent on the dose of
gefitinib in previous trials [1,2,9,10]. Even when the dose
of gefitinib was less than 250 mg/day, several responders
were documented [1,2]. However, the development of
adverse effects other than ILD is usually dependent on the
dose of gefitinib [1,2]. Therefore, re-treatment by a
reduced dose may be effective for patients who had previ-
ously responded to standard dose of gefitinib but had dis-
continued treatment due to the occurrence of severe
adverse events other than ILD. Due to the low incidence
of gefinitib-related ILD, it is difficult to show whether the
same hypothesis fit to the gefinitib-related ILD based on
the observational studies. Although there are no data indi-
cating the dose-dependency of ILD, we could successfully
manage a patient who had once developed ILD with a half
dose of gefitinib.
Numerous studies suggest that gefitinib has fairly effective
anti-tumor activity, especially for tumors with EGFR gene
mutations [11,12]. It is well-known that EGFR-mutated
tumors respond dramatically to lower dose of EGFR-TKIs
such as gefitinib in experimental studies [13,14]. These
findings may suggest that a reduced dose of gefitinib is
sufficient for tumors with these molecular characteristics,
and that the currently approved dose is excessively potent
in some of these patients and results in adverse events.
The prognosis of patients with lymphangitis carcinoma-
tosa is extremely poor, with approximately 50% of the
patients dying within three months of their first respira-
tory symptoms [15]. Fortunately, our patient was able to
spend the rest of his life at home without the relapse of
ILD for 16 months after readministration of gefitinib.
Therefore, a resumption of gefitinib therapy would be
clinically beneficial for him. However, secondary treat-
ment with gefitinib for a patient who once developed gef-
initib-related ILD is usually considered very risky.
Therefore, at this time, alternative therapeutic modalities
should be chosen, if available.
Conclusion
We herein presented the case of gefitinib readministration
in a patient with lung adenocarcinoma who had once
responded but in whom treatment had to be discontinued
owing to gefinitib-related ILD. Gefitinib readministration
with 50% dose was found to successfully control disease
progression.
We believe clinical trials are warranted to evaluate gefit-
inib readministration with a dose reduction for patients
who have once responded but later discontinued this
treatment owing to severe adverse events including ILD.
The appropriate dose and schedule of gefitinib readminis-
tration also should be determined in these trials.
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